CHRS Earnings & Financial Statements
Coherus Oncology, Inc.
$1.15
-$0.01(-1.29%)
44
Overall
80
Value
20
Tech
34
Quality
Market Cap
$179.22M
Volume
727.18K
52W Range
$1.09 - $2.62
Target Price
$7.75
CHRS earnings and financial statements: Coherus Oncology, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
CHRS Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $42.17M | $26.39M | $257.24M | $211.04M | $326.55M |
| Cost of revenue | $13.81M | $8.73M | $158.99M | $70.08M | $57.59M |
| Operating income | -$181.13M | -$199.65M | -$203.20M | -$256.88M | -$263.86M |
| EBITDA | -$170.48M | -$197.79M | -$191.53M | -$249.15M | -$260.69M |
| Net income | $168.02M | $28.51M | -$237.89M | -$291.75M | -$287.10M |
| EPS (diluted) | $1.43 | $0.25 | $-2.53 | $-3.76 | $-3.81 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $258.34M | $448.53M | $629.60M | $480.85M | $679.33M |
| Total liabilities | $197.33M | $580.52M | $823.03M | $618.26M | $581.61M |
| Shareholders’ equity | $61.01M | -$131.99M | -$193.43M | -$137.42M | $97.73M |
| Cash and equivalents | $88.88M | $125.99M | $102.89M | $63.55M | $417.19M |
| Long-term debt | - | $228.23M | $226.89M | $225.57M | $332.77M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$138.51M | -$20.44M | -$174.88M | -$241.12M | -$37.43M |
| Capital expenditure | $470.31M | $227.82M | -$286.0K | -$2.04M | -$1.29M |
| Free cash flow | $331.79M | $207.38M | -$174.88M | -$241.12M | -$38.72M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CHRS | $1.15 | -1.3% | 727.18K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |